EGFR exon 19 insertion EGFR-K745_E746insIPVAIK and others with rare XPVAIK amino-acid insertions: Preclinical and clinical characterization of the favorable therapeutic window to all classes of approved EGFR kinase inhibitors

EGFR exon 19 insertion EGFR-K745_E746insIPVAIK and others with rare XPVAIK amino-acid insertions: Preclinical and clinical characterization of the favorable therapeutic window to all classes of approved EGFR kinase inhibitors

•EGFR-K745_E746insIPVAIK and other exon 19 insertion mutations (

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Lung cancer (Amsterdam, Netherlands) Netherlands), 2023-07, Vol.181, p.107250-107250, Article 107250
Hauptverfasser: Shaffer, William, Kobayashi, Ikei S., Sentana-Lledo, Daniel, Sundararaman, Shriram, Lee, Meghan D., Rangachari, Deepa, VanderLaan, Paul A., Kobayashi, Susumu S., Costa, Daniel B.
Format: Artikel
Sprache:eng
Schlagworte:
Afatinib
Afatinib - therapeutic use
Amino Acids - genetics
Carcinoma, Non-Small-Cell Lung - drug therapy
EGFR exon 19 insertion
ErbB Receptors - genetics
Erlotinib
Erlotinib Hydrochloride - therapeutic use
Exons
Humans
K745_E746insIPVAIK
Lung cancer
Lung Neoplasms - drug therapy
Mobocertinib
Mutation
Osimertinib
Protein Kinase Inhibitors - therapeutic use
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:•EGFR-K745_E746insIPVAIK and other exon 19 insertion mutations (
ISSN:0169-5002
1872-8332
1872-8332
DOI:10.1016/j.lungcan.2023.107250